Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,054 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.
Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, Andrews N, Lal G, Riley C, Rahim R, Cartwright K, Allan G, Miller E. Borrow R, et al. Among authors: finn a. Infect Immun. 2003 Oct;71(10):5549-55. doi: 10.1128/IAI.71.10.5549-5555.2003. Infect Immun. 2003. PMID: 14500473 Free PMC article. Clinical Trial.
Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
Pace D, Khatami A, McKenna J, Campbell D, Attard-Montalto S, Birks J, Voysey M, White C, Finn A, Macloed E, Faust SN, Kent AL, Heath PT, Borrow R, Snape MD, Pollard AJ. Pace D, et al. Among authors: finn a. BMJ. 2015 Apr 1;350:h1554. doi: 10.1136/bmj.h1554. BMJ. 2015. PMID: 25832102 Free PMC article. Clinical Trial.
Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.
Pace D, Khatami A, Attard-Montalto S, Voysey M, Finn A, Faust SN, Heath PT, Borrow R, Snape MD, Pollard AJ. Pace D, et al. Among authors: finn a. Vaccine. 2016 Dec 7;34(50):6350-6357. doi: 10.1016/j.vaccine.2016.10.038. Epub 2016 Oct 28. Vaccine. 2016. PMID: 28029540 Clinical Trial.
Polysaccharide-specific memory B cells generated by conjugate vaccines in humans conform to the CD27+IgG+ isotype-switched memory B Cell phenotype and require contact-dependent signals from bystander T cells activated by bacterial proteins to differentiate into plasma cells.
Clarke ET, Williams NA, Findlow J, Borrow R, Heyderman RS, Finn A. Clarke ET, et al. Among authors: finn a. J Immunol. 2013 Dec 15;191(12):6071-83. doi: 10.4049/jimmunol.1203254. Epub 2013 Nov 13. J Immunol. 2013. PMID: 24227777
Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia.
Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C, Borrow R, Finn A, Kahler CM, Whelan J, Vadivelu K, Richmond P. Marshall HS, et al. Among authors: finn a. N Engl J Med. 2020 Jan 23;382(4):318-327. doi: 10.1056/NEJMoa1900236. N Engl J Med. 2020. PMID: 31971677 Clinical Trial.
H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study.
Walker WT, de Whalley P, Andrews N, Oeser C, Casey M, Michaelis L, Hoschler K, Harrill C, Moulsdale P, Thompson B, Jones C, Chalk J, Kerridge S, John TM, Okike I, Ladhani S, Tomlinson R, Heath PT, Miller E, Faust SN, Snape MD, Finn A, Pollard AJ. Walker WT, et al. Among authors: finn a. Clin Infect Dis. 2012 Mar 1;54(5):661-9. doi: 10.1093/cid/cir905. Epub 2012 Jan 19. Clin Infect Dis. 2012. PMID: 22267719 Free PMC article. Clinical Trial.
1,054 results